AbbVie Signs a Partner and Option to Acquire Agreement with TeneoOne for its TNB-383B
Shots:
- TeneoOne to receive $90M upfront and will take care of P-I trial for TNB-383B with its expected onset in H1’19. AbbVie to get exclusive WW rights to develop and commercialize Teneobio’s TNB-383B- with an option to acquire TeneoOne
- If AbbVie exercises option to acquire- TeneoOne will receive milestones on sales and regulatory approval of TNB-383B
- TNB-383B is a bispecific Ab used for targeting B-cell maturation antigen (BCMA) developed using TeneoOne’s anti-CD3 platform- will be evaluated in P-I for multiple myeloma
Ref: AbbVie | Image: AbbVie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com